NanaBis™
Phase 3Small molecule
NanaBis™ is one of 13 small molecule programs targeting Bone pain. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Bone Pain
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aleve
Alnylam PharmaceuticalsPhase 3
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Oxycodone IR
Johnson & JohnsonPhase 3
Claritin
PPerrigo Company
Phase 2
Aristan
NNational Cancer Institute (NCI)
Phase 2
Nexium
DDexcel Pharma Technologies Ltd.
Phase 2
Neulasta
AmgenPhase 1
Ibandronate Sodium
SSWOG Cancer Research Network
Phase 3
Resiniferatoxin
SSorrento Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NanaBis™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedlab Clinical